The U.S. Food and Drug Administration (FDA) has given its approval to Omvoh, a novel medication developed by Eli Lilly, for the treatment of ulcerative colitis. This injectable drug is the inaugural treatment for ulcerative colitis that specifically targets the p19 protein subunit, which plays a role in inflammation associated with the condition. The announcement was made in an official press release by Eli Lilly on October 26. Omvoh is set to be available in the U.S. market in the upcoming weeks. Notably, the drug had already received approval in Japan and the European Union earlier this year.